Thermo Fisher Scientific Inc. (TMO)
NYSE: TMO · Real-Time Price · USD
402.76
-12.57 (-3.03%)
At close: Jun 13, 2025, 4:00 PM
402.82
+0.06 (0.01%)
After-hours: Jun 13, 2025, 7:59 PM EDT
Thermo Fisher Revenue
Thermo Fisher had revenue of $10.36B in the quarter ending March 29, 2025, with 0.18% growth. This brings the company's revenue in the last twelve months to $42.90B, up 0.96% year-over-year. In the year 2024, Thermo Fisher had annual revenue of $42.88B with 0.05% growth.
Revenue (ttm)
$42.90B
Revenue Growth
+0.96%
P/S Ratio
3.58
Revenue / Employee
$343,184
Employees
125,000
Market Cap
152.04B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 42.88B | 22.00M | 0.05% |
Dec 31, 2023 | 42.86B | -2.06B | -4.58% |
Dec 31, 2022 | 44.92B | 5.70B | 14.55% |
Dec 31, 2021 | 39.21B | 6.99B | 21.71% |
Dec 31, 2020 | 32.22B | 6.68B | 26.14% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TMO News
- 21 hours ago - Report: Biotech Research Firm Thermo Fisher Considers Selling Diagnostics Business - PYMNTS
- 1 day ago - Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms - Business Wire
- 1 day ago - Thermo Fisher plans to sell parts of diagnostics unit for $4 billion, FT reports - Reuters
- 12 days ago - Thermo Fisher Scientific Unveils Next-generation Mass Spectrometers at ASMS 2025 to Revolutionize Biopharma Applications and Omics Research - Business Wire
- 12 days ago - Thermo Fisher: With A 30% Price Drop, Trump Legislation, And High Capex, Is It Undervalued? - Seeking Alpha
- 12 days ago - Thermo Fisher Is Strengthening Its Long-Term Advantage - Seeking Alpha
- 14 days ago - So Cheap It's Silly - 2 Dividend Stocks I'd Buy Twice If I Could - Seeking Alpha
- 16 days ago - Thermo Fisher Scientific Launches New Spectral Flow Cytometer Offering Increased Speed, Versatility and Reliability to Labs - Business Wire